The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking to enhance domestic biopharmaceutical manufacturing capabilities through a contract focused on onshoring the production of viral hemorrhagic fever vaccine candidates. The primary objective is to transfer the manufacturing processes for Vesicular Stomatitis Virus (VSV) Delta G based vaccine candidates from international sites to domestic Contract Development and Manufacturing Organizations (CDMOs) in the United States, thereby strengthening national health security preparedness against threats like the Marburg and Sudan viruses. This initiative is critical as it addresses the current limited domestic capacity for live viral vector manufacturing, ensuring a robust response to infectious disease challenges. Interested parties must be product sponsors or technology owners with BARDA-sponsored monovalent filovirus vaccine candidates and should prepare for a technology transfer demonstration, as the scope does not include procurement of investigational or licensed products.